Published Guidance, NICE advice and quality standards

Skip to filters Skip to results

Showing 1 to 25 of 754

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)	TA568	13 March 2019	13 March 2019
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	TA373	16 December 2015	16 December 2015
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	TA563	27 February 2019	27 February 2019
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	TA810	20 July 2022	20 July 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	TA725	15 September 2021	15 September 2021
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen	TA259	27 June 2012	27 July 2016
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	TA387	27 April 2016	27 July 2016
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	TA721	18 August 2021	18 August 2021
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	TA814	3 August 2022	3 August 2022
Acalabrutinib for treating chronic lymphocytic leukaemia	TA689	21 April 2021	21 April 2021
Adalimumab and dexamethasone for treating non-infectious uveitis	TA460	26 July 2017	26 July 2017
Adalimumab for the treatment of adults with psoriasis	TA146	25 June 2008	25 June 2008
Adalimumab for treating moderate to severe hidradenitis suppurativa	TA392	22 June 2016	22 June 2016
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	TA455	12 July 2017	12 July 2017
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed	TA715	14 July 2021	14 July 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	TA375	26 January 2016	26 January 2016
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	TA195	25 August 2010	25 August 2010
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B	TA96	22 February 2006	22 February 2006
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	TA444	24 May 2017	24 May 2017
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer	TA310	23 April 2014	23 April 2014
Aflibercept for treating choroidal neovascularisation	TA486	1 November 2017	1 November 2017
Aflibercept for treating diabetic macular oedema	TA346	22 July 2015	22 July 2015
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion	TA409	28 September 2016	28 September 2016
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion	TA305	26 February 2014	26 February 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	TA307	25 March 2014	25 March 2014

Results per page

10
25
50
All